Pacira BioSciences Inc Dossier
Qualitative Analysis
Business overview
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a specialty pharmaceutical company dedicated to providing non-opioid pain management and regenerative health solutions. The company's commercial portfolio is anchored by its flagship product, EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic designed for postsurgical pain management. Additionally, Pacira commercializes ZILRETTA, an extended-release intra-articular corticosteroid injection for osteoarthritis knee pain, and the iovera system, a handheld cryoanalgesia device that delivers controlled cold temperatures to block pain signals in peripheral nerves. Pacira is also advancing PCRX-201, a novel gene therapy vector platform targeting knee osteoarthritis.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A five-year strategic plan launched in January 2025 to transition Pacira into an innovative biopharmaceutical organization and a therapeutic area leader in musculoskeletal pain. The plan targets treating over 3 million patients annually, achieving double-digit compounded annual product revenue growth, improving gross margins by 5 percentage points over 2024, expanding the clinical pipeline with 5 novel programs, and establishing 5 strategic partnerships by 2030.
Expected impact: Aims to drive long-term shareholder value, diversify the product portfolio, and secure sustainable growth beyond the core EXPAREL franchise.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of the remaining 81% equity stake in GQ Bio to integrate its High-Capacity Adenovirus (HCAd) gene therapy vector platform. This platform supports the development of PCRX-201, a novel local gene therapy for knee osteoarthritis, by enabling efficient delivery of large gene constructs with lower doses.
Financial impact: Eliminated up to $64 million in potential future milestone payment obligations under the previous partnership agreement, including a $4.5 million milestone due upon Phase 2 trial initiation.
Strategic Partnerships
Secured exclusive global rights to develop and commercialize AMT-143, an investigational long-acting non-opioid anesthetic (ropivacaine hydrogel) for postsurgical pain control. This asset is highly complementary to EXPAREL and expands the pipeline under the 5x30 strategy.
Terms: Pacira paid an upfront fee of $5 million, with potential future development- and sales-based milestones of up to $225 million, plus tiered royalties on future net sales. Pacira is responsible for funding clinical development through commercial launch.
A strategic collaboration to co-promote ZILRETTA in the U.S. by leveraging J&J MedTech's specialized early intervention sales force. This expands ZILRETTA's reach beyond orthopedic practices into sports medicine, pain management, and rheumatology.
Terms: Specific financial terms were not disclosed, but the collaboration leverages existing commercial infrastructure to drive sales growth.
Granted LG Chem exclusive rights to commercialize EXPAREL in select Asian-Pacific markets, including South Korea and Thailand, expanding Pacira's global footprint.
Terms: Pacira received an upfront payment and will supply EXPAREL product, receiving a transfer price and tiered royalties on future commercial sales.